Cancer of breast

Breast cancer is the second most commonly diagnosed cancer worldwide, behind only lung cancers; this is even more remarkable when its relative rarity in males is noted (males

...


Read more on Cancer of breast

 

 

Latest news articles

Added 14 days ago Drug news

EMA approves Lynparza to treat patients with germline BRCA1/2-mutations (gBRCAm) with HER2-negative metastatic breast cancer

AstraZeneca and MSD Inc. have announced the European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of...

Added 20 days ago Drug news

FDA expands indication of Ibrance to include HER2- breast cancer in males

The FDA is extending the indication of Ibrance (palbociclib), from Pfizer, capsules in combination with specific endocrine therapies for hormone...

Added 20 days ago Drug news

Oncology Venture A/S acquires option from R-Pharm to the European rights for Ixempra to treat breast cancer.

Oncology Venture A/S announced that the company has obtained an exclusive option to in-license the European rights to Ixempra (ixabepilone)...

Search all news articles for Cancer of breast
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Guidelines

Advanced breast cancer: diagnosis and treatment

This guideline covers care and support for people with advanced (stage 4) breast cancer.

Added 10 years ago

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

The ESO-ESMO 3rd international consensus guidelines for advanced breast cancer (ABC3) focus on methodology, assessment guidelines and treatment recommendations for specific breast cancer subtypes...

Added 1 year ago

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The updated ESMO Clinical Practice Guidelines provide information on the current management of primary breast cancer, including screening, diagnosis and...

Added 3 years ago

Search all guidelines for Cancer of breast
 

Journal articles

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received...

Added 9 months ago

Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells.

Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis.

Added 10 months ago

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.

The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting.

Added 10 months ago

Search all journal articles for Cancer of breast
 

Clinical trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 1 year ago

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 1 year ago

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in...

Added 1 year ago

Search all clinical trials for Cancer of breast
 
Advances in Precision Cancer Care

Advances in Precision Cancer Care aims to bring you the latest news and some of the most exciting developments in precision cancer care.

Our first reports come from ESMO Congress 2018.

ESMO 2018 | Day 2 highlights

Saturday’s ESMO 2018 report comes from Presidential Symposium 1, moderated by Andrés Cervantes (Valencia, ES) and Josep Tabernero (Barcelona, ES), discussing the scientific results and clinical implications of new data from the phase 3 IMpassion130, PALOMA-3 and SOLAR-1 trials. 

CME

Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Cancer of breast